Barclays Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $3
Barclays Remains a Buy on Barinthus Biotherapeutics (BRNS)
Barinthus Biotherapeutics Price Target Cut to $9.50/Share From $11.00 by Alliance Global Partners
Barinthus Biotherapeutics Analyst Ratings
A. G. P. Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Cuts Target Price to $9.5
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $5 Price Target
Buy Rating Reaffirmed for Barinthus Biotherapeutics Amid Promising Clinical Advancements
Barinthus Biotherapeutics Analyst Ratings
Barinthus Biotherapeutics Analyst Ratings
HC Wainwright & Co. : The Barinthus Biotherapeutics (BRNS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.
Barinthus Biotherapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $8 Price Target
Buy Rating for Barinthus Biotherapeutics Backed by Strong Financials and Promising Clinical Trials
Analysts Offer Insights on Healthcare Companies: Barinthus Biotherapeutics (BRNS) and GoodRx Holdings (GDRX)
HC Wainwright & Co. : The Barinthus Biotherapeutics (BRNS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.
HC Wainwright & Co. : The Barinthus Biotherapeutics (BRNS.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $8.00.
Barinthus Biotherapeutics Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Barinthus Biotherapeutics, Maintains $8 Price Target
Buy Rating on Barinthus Biotherapeutics Backed by Promising Clinical Trials and Strong Valuation Prospects
Barinthus Biotherapeutics Analyst Ratings
No Data